Equities research analysts expect Relmada Therapeutics, Inc. (NASDAQ:RLMD – Get Rating) to report earnings of ($1.30) per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Relmada Therapeutics’ earnings, with estimates ranging from ($1.32) to ($1.27). Relmada Therapeutics posted earnings of ($1.56) per share during the same quarter last […]
Brokerages expect Relmada Therapeutics, Inc. (NASDAQ:RLMD – Get Rating) to announce ($1.21) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Relmada Therapeutics’ earnings. The lowest EPS estimate is ($1.26) and the highest is ($1.12). Relmada Therapeutics reported earnings per share of ($1.34) in […]
Relmada Therapeutics, Inc. (NASDAQ:RLMD – Get Rating)’s stock price shot up 2.6% on Tuesday . The stock traded as high as $30.78 and last traded at $30.73. 916 shares traded hands during mid-day trading, a decline of 100% from the average session volume of 339,304 shares. The stock had previously closed at $29.96. A number […]
Relmada Therapeutics (NASDAQ:RLMD – Get Rating) will issue its quarterly earnings data after the market closes on Wednesday, March 23rd. Analysts expect the company to announce earnings of ($1.47) per share for the quarter. Parties that are interested in participating in the company’s conference call can do so using this link. Shares of NASDAQ RLMD […]